drugset
Drugs / LOMIBUVIR
last change Jun 2014 re-read 2 minutes ago

LOMIBUVIR

also known as VX-222 · VCH-222

Small molecule

Developed for
chronic hepatitis C virus infection
Investigated by
Vertex Pharmaceuticals Incorporated · ViroChem Pharma

Trials 5 · a red edge is where a trial was stopped

today NCT01581138 · Ph 2 NCT01516918 · Ph 2 NCT01080222 · Ph 2 NCT00958152 · Ph 1 NCT00911963 · Ph 1/2
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00958152 Aug 2009 → Jan 2010 hepatitis C virus infection Vertex Pharmaceuticals Incorporated Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00911963 Apr 2009 → Sep 2012 chronic hepatitis C virus infection Vertex Pharmaceuticals Incorporated Completed No outcome recorded
Phase 23 trials
Phase 2 NCT01581138 Jul 2012 → Jun 2013 chronic hepatitis C virus infection Vertex Pharmaceuticals Incorporated Completed No outcome recorded
Phase 2 NCT01516918 Feb 2012 → Sep 2013 chronic hepatitis C virus infection Vertex Pharmaceuticals Incorporated Completed No outcome recorded
Phase 2 NCT01080222 Aug 2010 → Oct 2013 chronic hepatitis C virus infection Vertex Pharmaceuticals Incorporated Terminated No outcome recorded

Press releases naming this drug 10 releases

DateIssuerRelease
2012-02-23 Vertex Pharmaceuticals Incorporated Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of INCIVEK®, VX-222 and Ribavirin in People with Genotype 1 Hepatitis C vrtx.com ↗
2011-11-05 Vertex Pharmaceuticals Incorporated Interim Data from Phase 2 Study Showed 93% of People with Hepatitis C Who Received a Total of 12 Weeks of a Combination Regimen Including INCIVEK™ (telaprevir) and VX-222 (400mg) Achieved a Viral Cure (SVR) vrtx.com ↗
2011-07-26 Vertex Pharmaceuticals Incorporated Interim Data from Phase 2 Study of Combination Regimen Including VX-222 and INCIVEK™ Suggest Potential to Treat Genotype 1 Hepatitis C in as few as 12 Weeks and No More Than 24 Weeks vrtx.com ↗
2011-03-31 Vertex Pharmaceuticals Incorporated Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C vrtx.com ↗
2011-03-07 Vertex Pharmaceuticals Incorporated New Data on Telaprevir and VX-222 for the Treatment of Hepatitis C Accepted For Presentation at EASL Annual Meeting vrtx.com ↗
2010-12-21 Vertex Pharmaceuticals Incorporated Vertex Provides Update to Ongoing Phase 2 Study Evaluating Combinations of Telaprevir and VX-222 for the Treatment of Hepatitis C vrtx.com ↗
2010-11-10 Vertex Pharmaceuticals Incorporated Vertex Announces Plans to Enroll Additional Treatment Arm in Ongoing Phase 2 Combination Study of Telaprevir and VX-222 for the Treatment of People with Hepatitis C vrtx.com ↗
2010-04-15 Vertex Pharmaceuticals Incorporated Hepatitis C Virus Polymerase Inhibitor VX-222 Reduced Viral Levels Over Three Days in Phase 1b Trial vrtx.com ↗
2010-03-16 Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual Meeting vrtx.com ↗
2009-03-18 Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VCH-222 Abstracts for Presentation at EASL Annual Meeting vrtx.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as LOMIBUVIR ChEMBL registry synonym — accepted as the source's own label CHEMBL3039503 ↗
Known as VCH-222 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00911963 ↗
1

NCT00958152 ↗
Known as VX-222 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01516918 ↗
2

NCT01581138 ↗

NCT01080222 ↗
Action Inhibit “selective nonnucleoside inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase” PMID 24982088 ↗ Jun 2014
Modality Small molecule “VX-222, a thiophene-2-carboxylic acid derivative” PMID 24982088 ↗ Jun 2014
Route Oral “capsule, oral, 400 mg twice daily or 750 mg twice daily, 12 weeks” NCT00911963 ↗